Asthika Goonewardene

Stock Analyst at Truist Securities

(2.15)
# 2,885
Out of 5,124 analysts
94
Total ratings
40.22%
Success rate
-3%
Average return

Stocks Rated by Asthika Goonewardene

Zymeworks
Dec 17, 2025
Initiates: Buy
Price Target: $40
Current: $24.18
Upside: +65.43%
ArriVent BioPharma
Nov 25, 2025
Initiates: Buy
Price Target: $43
Current: $18.93
Upside: +127.15%
Mersana Therapeutics
Nov 13, 2025
Downgrades: Hold
Price Target: $36$31
Current: $29.30
Upside: +4.95%
Genmab
Nov 7, 2025
Reiterates: Buy
Price Target: $49$48
Current: $33.10
Upside: +45.02%
Gilead Sciences
Nov 3, 2025
Reiterates: Buy
Price Target: $127$145
Current: $121.36
Upside: +19.48%
Arcus Biosciences
Oct 7, 2025
Reiterates: Buy
Price Target: $32$39
Current: $21.69
Upside: +79.81%
Janux Therapeutics
Sep 10, 2025
Initiates: Buy
Price Target: $100
Current: $13.44
Upside: +644.05%
Revolution Medicines
Sep 5, 2025
Initiates: Buy
Price Target: $99
Current: $79.85
Upside: +23.98%
Exelixis
Jul 29, 2025
Maintains: Buy
Price Target: $56$49
Current: $43.68
Upside: +12.18%
BioNTech SE
Jun 3, 2025
Reiterates: Buy
Price Target: $151$155
Current: $98.09
Upside: +58.02%
Maintains: Buy
Price Target: $88$71
Current: $20.98
Upside: +238.42%
Maintains: Buy
Price Target: $14$10
Current: $1.41
Upside: +609.22%
Maintains: Buy
Price Target: $11$10
Current: $2.00
Upside: +400.00%
Maintains: Buy
Price Target: $25$15
Current: $2.55
Upside: +488.24%
Initiates: Buy
Price Target: $35
Current: $18.66
Upside: +87.57%
Maintains: Buy
Price Target: $87$136
Current: $62.01
Upside: +119.32%
Maintains: Buy
Price Target: $180$150
Current: $11.52
Upside: +1,202.08%
Maintains: Buy
Price Target: $5$4
Current: $1.55
Upside: +158.06%
Maintains: Buy
Price Target: $19
Current: $1.72
Upside: +1,004.65%
Reiterates: Buy
Price Target: $432
Current: $8.05
Upside: +5,266.46%
Reinstates: Hold
Price Target: $120
Current: $6.66
Upside: +1,701.80%
Maintains: Hold
Price Target: $100$60
Current: $1.25
Upside: +4,700.00%
Maintains: Buy
Price Target: $228$180
Current: $12.99
Upside: +1,285.68%